COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis

Abstract excerpt

BACKGROUND: In the aftermath of Covid-19, some patients develop a fibrotic lung disease, i.e., post-COVID-19 lung disease (PCLD), for which we currently lack insights into pathogenesis, disease models, or treatment options. METHODS: Using an AI-guided approach, we analyzed > 1000 human lung transcriptomic datasets associated with various lung conditions using two viral pandemic signatures (ViP and sViP) and one...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Inflammatory Myopathies and Dermatomyositis
• Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
• Share to Long-Term Effects of COVID-19